Inducible nitric oxide synthase expression in gastric adenocarcinoma: Impact on lymphangiogenesis and lymphatic metastasis

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Karadayi, Nimet ^a   Kandemir, Nilufer O ^b   Yavuzer, Dilek ^a   Korkmaz, Taner ^a   Gecmen, Gonca ^a   Kokturk, Furuzan ^b  

^a Dr Lutfi Kirdar Training and Research Hospital   (Turkey)

^b ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Gastric carcinoma; Inducible nitric oxide synthases; Lymph node metastasis; Lymphangiogenesis

Indexed keywords

DIAGNOSTIC AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; NOS2 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHEMISTRY; ENZYMOLOGY; FEMALE; GASTRECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; TUMOR INVASION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CASE-CONTROL STUDIES; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NITRIC OXIDE SYNTHASE TYPE II; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883878100     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-151     Document Type: Article

References (46)

1. Yamaguchi T, Fujimori T, Tomita S, Ichikawa K, Mitomi H, Ohno K, Shida Y, Kato H. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence. Diagn Pathol 2013, 22(8):65.
2. Ziche M, Morbidelli L. Molecular regulation of tumour angiogenesis by nitric oxide. Eur Cytokine Netw 2009, 20(4):164-170.
3. Singh S, Gupta AK. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 2011, 67(6):1211-1224. 10.1007/s00280-011-1654-4, 21544630.
4. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013, 34(3):503-512. 10.1093/carcin/bgt034, 23354310.
5. Zhang W, He XJ, Ma YY, Wang HJ, Xia YJ, Zhao ZS, Ye ZY, Tao HQ. Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients. Hum Pathol 2011, 42(9):1275-1282. 10.1016/j.humpath.2010.09.020, 21333324.
6. Lahdenranta J, Hagendoorn J, Padera TP, Hoshida T, Nelson G, Kashiwagi S, Jain RK, Fukumura D. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 2009, 69(7):2801-2808. 10.1158/0008-5472.CAN-08-4051, 2670480, 19318557.
7. Massi D, De Nisi MC, Franchi A, Mourmouras V, Baroni G, Panelos J, Santucci M, Miracco C. Inducible nitric oxide synthase expression in melanoma: implications in lymphangiogenesis. Mod Pathol 2009, 22(1):21-30. 10.1038/modpathol.2008.128, 18660796.
8. Franchi A, Massi D, Santucci M, Masini E, Rossi Degl'Innocenti D, Magnelli L, Fanti E, Naldini A, Ardinghi C, Carraro F, Gallo O. Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J Pathol 2006, 208(3):439-445. 10.1002/path.1892, 16278821.
9. Rajnakova A, Moochhala S, Goh PM, Ngoi S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 2001, 172:177-185. 10.1016/S0304-3835(01)00645-0, 11566494.
10. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer 2002, 2:8-14. 10.1186/1471-2407-2-8, 113262, 11978184.
11. Wang YZ, Cao YQ, Wu JN, Chen M, Cha XY. Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. World J Gastroenterol 2005, 11(1):46-50.
12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual 2010, 299-323. New York: Springer-Verlag, 7.
13. Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol 2013, 9(8):76.
14. Bosman FT. WHO classification of tumours of the digestive system 2010, Lyon: IARC Press, 4, World health organization; i{dotless}nternational agency for research on cancer.
15. Sotoudeh K, Hashemi F, Madjd Z, Sadeghipour A, Molanaei S, Kalantary E. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol 2012, 28(7):57.
16. Yamauchi C, Hasebe T, Iwasaki M, Imoto S, Wada N, Fukayama M, Ochiai A. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol 2007, 38:247-259. 10.1016/j.humpath.2006.07.017, 17056095.
17. Klintrup K, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005, 41(17):2645-2654. 10.1016/j.ejca.2005.07.017, 16239109.
18. Li LG, Xu HM. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol 2005, 11(17):2539-2544.
19. Koh E, Noh SH, Lee YD, Lee HY, Han JW, Lee HW, Hong S. Differential expression of nitric oxide synthase in human stomach cancer. Cancer Lett 1999, 146(2):173-180. 10.1016/S0304-3835(99)00265-7, 10656623.
20. Puhakka A, Kinnula V, Näpänkangas U, Säily M, Koistinen P, Pääkkö P, Soini Y. High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. APMIS 2003, 111(12):1137-1146. 10.1111/j.1600-0463.2003.apm1111210.x, 14678024.
21. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002, 167:2032-2035. 10.1016/S0022-5347(05)65077-X, 11956432.
22. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36:169-180. 10.1007/BF00666038, 8534865.
23. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Beliën JA, de Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL, Dirix LY. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002, 38(12):1564-1579. 10.1016/S0959-8049(02)00094-1, 12142044.
24. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer 2006, 95(12):1611-1625. 10.1038/sj.bjc.6603445, 2360768, 17117184.
25. Kawamura L, Carvalho FM, Alves BG, Bacchi CE, Goes JC, Calil MA, Baracat EC, Carvalho JP. Association between intratumoral lymphatic microvessel density (LMVD) and clinicopathologic features in endometrial cancer: a retrospective cohort study. World J Surg Oncol 2010, 8:89. doi:10.1186/1477-7819-8-89, 10.1186/1477-7819-8-89, 2964720, 20946633.
26. Kandemir NO, Barut F, Bektas S, Ozdamar SO. Can lymphatic vascular density be used in determining metastatic spreading potential of tumor in invasive ductal carcinomas?. Pathol Oncol Res 2012, 18(2):253-262. 10.1007/s12253-011-9436-1, 21785902.
27. Jin J, Jin T, Quan M, Piao Y, Lin Z. Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagn Pathol 2012, 5(7):135.
28. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. EMT: i{dotless}nvasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells Tissues Organs 2005, 179:56-65. 10.1159/000084509, 15942193.
29. Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 1998, 17(1):107-118. 10.1023/A:1005912906436, 9544426.
30. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008, 216(2):347-354. 10.1002/jcp.21494, 18481261.
31. Weryńska B, Dziegiel P, Jankowska R. Role of lymphangiogenesis in lung cancer. Folia Histochem Cytobiol 2009, 47(3):333-342.
32. Khromova N, Kopnin P, Rybko V, Kopnin BP. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2012, 31(11):1389-1397. 10.1038/onc.2011.330, 21804602.
33. Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 2005, 11(21):7637-7642. 10.1158/1078-0432.CCR-05-1142, 16278382.
34. Miyahara M, Tanuma J, Sugihara K, Semba I. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer 2007, 110(6):1287-1294. 10.1002/cncr.22900, 17674352.
35. Agarwal B, Saxena R, Morimiya A, Mehrotra S, Badve S. Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol 2005, 29(11):1449-1455. 10.1097/01.pas.0000174269.99459.9d, 16224211.
36. van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-Franse LV, Griffioen AW. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 2007, 254(1):128-136. 10.1016/j.canlet.2007.03.001, 17442484.
37. Zhao YC, Ni XJ, Li Y, Dai M, Yuan ZX, Zhu YY, Luo CY. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. World J Surg Oncol 2012, 10:165. 10.1186/1477-7819-10-165, 3499230, 22906075.
38. Weiss L. The pathobiology of metastasis within the lymphatic system. Surg Oncol Clin N Am 1996, 5(1):15-24.
39. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012, 31(42):4499-4508. 10.1038/onc.2011.602, 22179834.
40. Ogiya A, Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002, 82:1255-1257. 10.1097/01.LAB.0000028824.03032.AB, 12218087.
41. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol 2011, 193(4):607-618. 10.1083/jcb.201012094, 3166860, 21576390.
42. Wang XL, Fang JP, Tang RY, Chen XM. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer 2010, 10:299. 10.1186/1471-2407-10-299, 2906480, 20565772.
43. Gao P, Zhou GY, Zhang QH, Xiang L, Zhang SL, Li C, Sun YL. Clinicopathological significance of peritumoral lymphatic vessel density in gastric carcinoma. Cancer Lett 2008, 263(2):223-230. 10.1016/j.canlet.2008.01.017, 18289774.
44. Lin M, Ma SP, Lin HZ, Ji P, Xie D, Yu JX. Intratumoral as well as peritumoral lymphatic vessel invasion correlates with lymph node metastasis and unfavourable outcome in colorectal cancer. Clin Exp Metastasis 2010, 27(3):123-132. 10.1007/s10585-010-9309-0, 20195706.
45. Coşkun U, Akyürek N, Dursun A, Yamaç D. Peritumoral lymphatic microvessel density associated with tumor progression and poor prognosis in gastric carcinoma. J Surg Res 2010, 164(1):110-115. 10.1016/j.jss.2009.03.081, 19628230.
46. Lee K, Park Do J, Choe G, Kim HH, Kim WH, Lee HS. Increased intratumoral lymphatic vessel density correlates with lymph node metastasis in early gastric carcinoma. Ann Surg Oncol 2010, 17(1):73-80. 10.1245/s10434-009-0707-y, 19777179.